Effectiveness and safety of upadacitinib in a real-world cohort of patients with Crohn's disease in the UK: a multicentre retrospective cohort study.

ABSTRACT:

Objective

Upadacitinib is the first Janus kinase inhibitor and oral advanced therapy licensed for Crohn's disease (CD). Following NICE approval in 2023, real-world data on outcomes are limited. The effectiveness and safety of upadacitinib in a cohort of patients with CD was assessed.

Methods

A multicentre retrospective cohort analysis across 19 UK hospitals. Adult patients with active CD who started upadacitinib between April 2023 and October 2023 were included. Outcomes were reviewed over 24 weeks. The primary endpoint was clinical remission (Harvey Bradshaw Index (HBI) <4) at 12 and 24 weeks. Biochemical remission (faecal calprotectin <200 μg/g and C-reactive protein ≤5) and endoscopic remission (Simple Endoscopic Score for Crohn's Disease ≤3) were assessed at the same int

SUBMITTER: Danso Y 

PROVIDER: S-EPMC12506220 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature